Search the Newsreel

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

Stolper Co Purchases 3,648 Shares of International Business Machines Corporation $IBM

Stolper Co increased its stake in International Business Machines (IBM) by 29%, acquiring an additional 3,648 shares, bringing its total holdings to 16,248 shares valued at approximately $4.6 million. Institutional investors collectively own 58.96% of IBM, which recently met earnings expectations but saw revenue …

International Business Machines Corporation $IBM Stake Increased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC significantly increased its stake in International Business Machines (IBM) by 7.8% during the second quarter, now holding 665,812 shares valued at $187.2 million. Institutional investors and hedge funds own 58.96% of IBM, with major holders including Vanguard and State …

Milestone Asset Management LLC Increases Position in International Business Machines Corporation $IBM

Milestone Asset Management LLC significantly increased its stake in International Business Machines (IBM) by 36.9% in Q2, bringing its total holdings to 11,240 shares valued at $3.16 million. Despite mixed analyst ratings, with an average "Moderate Buy" consensus and a target price of $265.40, …

QRG Capital Management Inc. Buys 10,627 Shares of International Business Machines Corporation $IBM

QRG Capital Management Inc. increased its stake in International Business Machines Corporation (IBM) by 6.6% in the second quarter, now holding 172,688 shares valued at approximately $48.6 million. Other institutional investors also adjusted their positions, contributing to institutional ownership of 58.96%. IBM reported quarterly …

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

The Top 5 Analyst Questions From MACOM’s Q2 Earnings Call

The Top 5 Analyst Questions From MACOM's Q2 Earnings Call MACOM's second quarter was marked by significant revenue growth and strong market reaction, reflecting an acceleration in demand across its core end markets. Management attributed the quarter's performance to heightened demand for high-speed connectivity …

Redcare Pharmacy Aktie • A2AR94 • NL0012044747

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …

Bank of America Corp DE Buys 1,231,188 Shares of Intuitive Machines, Inc. $LUNR

IONS Stock Jumps 4% After-Hours — Goldman Sachs Lifts Price Target On Tryngolza Approval

Fisher Funds Management LTD Trims Stock Holdings in International Business Machines Corporation $IBM

Fisher Funds Management LTD reduced its stake in International Business Machines Corporation (IBM) by 5.5% in the second quarter, now holding 65,349 shares valued at $18.377 million. Other institutional investors also adjusted their positions in IBM. The article also covers recent positive and negative …

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $16.92 Million Stake in International Business Machines Corporation $IBM

Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in International Business Machines Corporation by 5.4% in the second quarter, bringing its total holdings to $16.92 million. Several other institutional investors also adjusted their positions in IBM. The article also provides a …

Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Humacyte (NASDAQ:HUMA) to a "strong sell" rating, though the broader analyst consensus remains a "Moderate Buy" with a $6.11 price target. The company reported a quarterly loss of $0.16 per share, missing estimates by $0.05, and revenue of $0.41 million, …

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from Analysts

NRx Pharmaceuticals (NASDAQ:NRXP) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $34.50. Despite this, the company recently missed its quarterly earnings and revenue estimates. Hedge funds and institutional investors hold 4.27% of the stock.

Vertex (VRTX) Stock Looks Above Fair Value On Earnings Yet About Right Overall

Vertex Pharmaceuticals (VRTX) has seen strong multi-year performance, with a 158.2% return over the past five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. The stock trades at 29.1x earnings, slightly above Simply Wall St's fair P/E estimate …

ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Wall Street Zen has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from a "buy" to a "strong-buy" rating. This upgrade follows Regeneron's strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Despite positive news regarding pipeline expansion and collaborations, the company faces risks …

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen has upgraded Inovio Pharmaceuticals (NASDAQ:INO) from a "Sell" to a "Hold" rating, though overall analyst opinions remain mixed, with MarketBeat reporting a "Moderate Buy" consensus. The company recently exceeded earnings estimates, reporting a quarterly EPS of negative $0.07 against an expected …

Mach Natural Resources (NYSE:MNR) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Mach Natural Resources (NYSE:MNR) from a "hold" to a "buy" rating, contributing to a consensus "Moderate Buy" rating with an average price target of $17.60. Shares opened at $13.01, close to their 50-day moving average, and institutional ownership is …

Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121

Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded Eledon Pharmaceuticals (NASDAQ:ELDN) from "strong sell" to "sell," though the broader analyst consensus remains "Hold" with a $9.67 target price. The company reported a quarterly loss of $0.27 per share, missing estimates, and its shares opened at $3.54. Institutional investors …

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen has upgraded Oramed Pharmaceuticals (NASDAQ:ORMP) from a "hold" to a "buy" rating, though MarketBeat's overall analyst rating for the company remains "Hold." Oramed Pharmaceuticals opened at $4.48, with a market capitalization of $186.35 million. The company recently reported a quarterly loss …

LUNR Stock Hits 52-Week High Ahead Of Q1 Earnings This Week — Retail Says SpaceX IPO Will Fuel A Rally In Intuitive Machines Shares

LB Pharmaceuticals (NASDAQ:LBRX) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded LB Pharmaceuticals (NASDAQ:LBRX) from "hold" to "sell" despite a broader analyst consensus of "Moderate Buy" with an average price target of $47.75. The company recently reported a quarterly loss of $1.71 per share, missing consensus estimates, and analysts anticipate a …

NRx Pharmaceuticals (NASDAQ:NRXP) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded NRx Pharmaceuticals (NASDAQ:NRXP) from a "hold" to a "sell" rating, despite other analysts maintaining a "Moderate Buy" consensus with an average price target of $34.50. The company's stock opened at $3.27, reflecting a 2.1% drop, and recently reported a …

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

Wall Street Zen downgraded Verrica Pharmaceuticals (NASDAQ:VRCA) from a "sell" to a "strong sell" rating. Despite this, the stock has a consensus "Hold" rating and an average target price of $14.50 from other analysts. The company recently reported a quarterly loss of $0.41 per …

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

BioCryst Pharmaceuticals reported a significant profit swing in Q2 2026, with revenue of US$218.25 million and net income of US$78.4 million, prompting a raised full-year revenue outlook to US$690 million–US$715 million. Despite this strong quarter, the company still faces a substantial year-to-date net loss …